Unlocking discovery of next-generation multispecific biologics for targeted cancer therapies

解锁用于靶向癌症治疗的下一代多特异性生物制剂的发现

• 批准号: 10061560
• 金额: $ 44.52万
• 依托单位: VALINK THERAPEUTICS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10061560
• 关键词: Unlocking; discovery; next; generation; multispecific

Monoclonal antibodies have emerged as the Standard of Care for late-stage cancers; however, resistance (whether primary or acquired) is a major issue. Clinical efficacy of monospecific antibodies remains limited, particularly in the case of advanced solid tumours.Multispecific biologics show great promise in overcoming the treatment shortcomings of monospecific antibodies. With binding sites targeting multiple signalling pathways, multispecific antibodies decrease the likelihood of primary or acquired resistance and increase clinical efficacy, preventing and/or delaying pathogenesis. Most importantly, multispecific biologics enable new mechanisms of action to eradicate cancer cells, not otherwise possible with traditional antibodies. To date, seven bispecific antibodies have received market approval and over 50 are in clinical trials.However, the discovery of multispecific biologics remains severely restricted by the lack of high-throughput assembly and screening technologies for multispecifics. Discovery of multispecifics is further complicated by the number of potential targets, combinatorial binder/format spaces, and complex (often unknown) mechanisms of action.LiliumX is a UK-based start-up (SME), spun out from the University of Oxford in 2021, co-founded by Drs Arne Scheu and Irsyad Khairil. We have developed a transformative and proprietary platform technology for high-throughput assembly and screening of multispecific biologics. We have graduated from Y Combinator and Creative Destruction Lab, filed a patent application to protect our Universal Assembly Platform, and raised investment from leading venture capitalists.With Smart funding, we will further develop and validate the performance of our Universal Assembly Platform for multispecific biologics discovery, demonstrating that we can create viable assets, through the pipeline from discovery to _in vivo_ studies.For 50 years, the UK has led the world in developing monoclonal antibody drugs. Innovate UK Smart funding to develop and validate LiliumX's Universal Assembly Platform will position the UK to lead the way for the next 50 years, developing and commercialising next-generation multispecific biologics.

单克隆抗体已成为晚期癌症的标准治疗;然而，耐药性（无论是原发性还是获得性）是一个主要问题。单特异性抗体的临床疗效仍然有限，特别是在晚期实体瘤的情况下。多特异性生物制剂在克服单特异性抗体的治疗缺点方面显示出巨大的前景。通过靶向多个信号传导途径的结合位点，多特异性抗体降低了原发性或获得性耐药的可能性，并提高了临床疗效，预防和/或延迟了发病机制。最重要的是，多特异性生物制剂能够实现新的作用机制来根除癌细胞，这是传统抗体无法实现的。迄今为止，已有7种双特异性抗体获得上市批准，50多种抗体正在进行临床试验，但由于缺乏高通量的多特异性抗体组装和筛选技术，多特异性生物制剂的发现仍然受到严重限制。LiliumX是一家总部位于英国的初创企业（SME），于2021年从牛津大学分拆出来，由阿恩·朔伊（Arne Scheu）博士和伊尔斯亚德·卡里尔（Irsyad Khairil）博士共同创立。我们开发了一种变革性的专有平台技术，用于高通量组装和筛选多特异性生物制剂。我们已经从Y Combinator和Creative Destruction Lab毕业，提交了专利申请以保护我们的通用组装平台，并从领先的风险投资家那里筹集了投资。在Smart的资助下，我们将进一步开发和验证我们的通用组装平台用于多特异性生物制剂发现的性能，证明我们可以创造可行的资产，50年来，英国在开发单克隆抗体药物方面一直处于世界领先地位。Innovate UK Smart资助开发和验证LiliumX的通用组装平台将使英国在未来50年内处于领先地位，开发和商业化下一代多特异性生物制剂。